Medications for Carcinoma In Situ Of Bladder

3 results

  • adstiladrin - nadofaragene firadenovec - vncg suspension

    (Nadofaragene Firadenovec-Vncg)
    Ferring Pharmaceuticals Inc.
    Adstiladrin treats adults with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, with or without papillary tumors.
    Medication Details

  • anktiva - nogapendekin alfa inbakicept - pmln solution

    (Nogapendekin Alfa Inbakicept-Pmln)
    Altor Bioscience, Llc, An Indirect Wholly-Owned Subsidiary Of Immunitybio, Inc.
    Anktiva, combined with BCG, treats adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, with or without papillary tumors.
    Medication Details
    Drug Interactions

  • valstar - valrubicin solution, concentrate

    (Valrubicin)
    Endo Usa, Inc.
    VALSTAR treats BCG-refractory carcinoma in situ (CIS) of the urinary bladder via intravesical therapy in patients for whom immediate cystectomy carries unacceptable morbidity or mortality risk.
    Medication Details
    Drug Interactions